# A Study to Evaluate the Efficacy of FK949E in Bipolar Disorder Patients With Major Depressive Episodes

> **NCT01725308** · PHASE2,PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 431 (actual)

## Conditions studied

- Bipolar Disorder

## Interventions

- **DRUG:** FK949E
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01725308
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02-07
- **Primary completion:** 2015-08-01
- **Final completion:** 2016-07-11
- **Target enrollment:** 431 (ACTUAL)
- **Last updated:** 2024-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01725308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01725308, "A Study to Evaluate the Efficacy of FK949E in Bipolar Disorder Patients With Major Depressive Episodes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01725308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*